Genmab — Januar 2014
-
nu hexa
-
applicable to a large number of diseases
-
can repurpose candidates - can supercharge candidates
-
expected to show robust growth in future
-
nu financial guidance
-
ikke noget nyt - dog 60% er eksterne omkostninger
-
key targets for 2014
-
4 studier readouts
-
expect to start new studies with dara
-
expect new partnerships på både duo og hexa
-
significatn milestones på dara
-
cash runway well over 7 years
-
speedsnakken er overstået - nu jazz
-
rigtig god præsentation
-
de går til breakout room med Eatwell. Det hører vi nok ikke...
-
har er god til at gennemgå det hele på 25 min. flere deals på vej på både duo og hexa
-
og massere at nye darastudier kommer frem i aller former for MM + udenfor mm også
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind